eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
1/2007
vol. 3
 
Share:
Share:
more
 
 
abstract:

Original paper
Insulin growth factor-1 and insulin growth factor binding protein-3 in Egyptian patients with chronic hepatitis C

Hala Mohamed Raslan
,
Wafaa Mohamed Ezzat
,
Mohamed Mahmoud Ahmed
,
Enas Abdel Rasheed

Arch Med Sci 2007; 3, 1: 46-51
Online publish date: 2007/03/23
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction: The liver is the major source of insulin growth factor-1 (IGF-1) and its main binding protein, insulin growth factor binding protein-3 (IGFBP-3), which modify its bioavailability, and their concentrations might reflect liver synthetic capacity. The aim of the study was to evaluate serum levels of IGF-1 and IGFBP-3 in patients with chronic hepatitis C and their potential use as a marker of hepatic synthetic capacity. Material and methods: Thirty patients with chronic hepatitis C virus infection were included in the study: 16 patients with chronic hepatitis and 14 patients with liver cirrhosis. Thirteen healthy volunteers, age and sex matched with the cases, were used as a control group. Serum IGF-1 and IGFBP-3 were measured in all patients and controls by enzyme-linked immunosorbent assay (ELISA). Results: Serum levels of IGF-1 in patients with liver cirrhosis were significantly lower than those in patients with chronic hepatitis and those in healthy controls (110.4±57 ng/ml, 308.1±188.5 ng/ml and 274.1±81.6 ng/ml respectively, p<0.001). IGF-1 correlated negatively with age and AST (r=-0.467 and -0.393 respectively, p £0.05), and positively with prothrombin concentration (r=0.461, p=0.05). Serum levels of IGFBP-3 were significantly lower in patients with chronic hepatitis and liver cirrhosis than those in healthy controls (3576.8±743.5 ng/ml, 2323.1±1073.1 ng/ml and 4675.1±1274.2 ng/ml respectively, p<0.001) with a significant difference between patients with liver cirrhosis and patients with chronic hepatitis (p<0.001). Also IGFBP-3 was significantly lower in patients with schistosoma infection than in patients without schistosoma (2648.3±838.1 ng/ml and 4058±1513.4 ng/ml respectively, p=0.002). IGFPP-3 correlated negatively with age and AST (r=-0.485 and -0.619 respectively, p<0.001) and positively with serum albumin and prothrombin concentration (r=0.509 and 0.617 respectively, p=0.02 and 0.006 respectively). Conclusions: IGF-1 and IGFBP-3 may be useful parameters for assessment of liver function. IGFBP-3 is an early predictor of hepatic dysfunction and can be used as a marker for the severity of liver disease.
keywords:

IGF-1, IGFBP-3, chronic hepatitis, liver cirrhosis

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe